New York City, NY – According to filings with the U.S. Securities and Exchange Commission, Phosplatin Therapeutics is raising $18,400,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Robert Fallon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Phosplatin Therapeutics

Phosplatin Therapeutics is a private, clinical stage drug development company focusing on oncology therapeutics, running multiple clinical trials in the US and Europe. The company’s lead drug candidate, PT-112, has a pleiotropic mechanism of action and induces immunogenic cell death (ICD), as a monotherapy and in combination with checkpoint inhibition. Our mission is to develop safe and effective novel therapies for cancer treatment worldwide.

To learn more about Phosplatin Therapeutics, visit http://phosplatin.com/

Contact:
Robert Fallon, President and Chief Executive Officer
646-380-2441

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved